Heparin kinetics in venous thrombosis and pulmonary embolism
- PMID: 1253392
- DOI: 10.1161/01.cir.53.4.691
Heparin kinetics in venous thrombosis and pulmonary embolism
Abstract
The response to a standard dose of heparin was studied in 20 patients with venous thromboembolism. The heparin regimen consisted of intravenous injection of 70 units per kg, followed after 90 minutes by a maintenance dose of 400 units per kg per 24 hours given by continuous infusion. Plasma heparin activity and the activated partial thromboplastin time (APTT) were measured at intervals to determine clearance of the initial injection and the response to maintenance dose. Large inter-individual variations were found in the anticoagulant effect and these were due in part to differences in heparin clearance and in part to differences in the APTT response to given amounts of heparin (heparin effect index). The heparin half-life was 63 +/- 15 minutes when plasma heparin activities were used for this calculation and 84 +/- 71.5 minutes when the APTT was used. These results are similar to values previously reported in normal volunteers. Four of the 20 patients had pulmonary embolism and in these heparin half-life was significantly shortened (P less than 0.005).
Similar articles
-
Heparin therapy for venous thrombosis and pulmonary embolism.Blood Rev. 1988 Dec;2(4):251-8. doi: 10.1016/0268-960x(88)90014-8. Blood Rev. 1988. PMID: 3061531 Review.
-
Circadian changes in anticoagulant effect of heparin infused at a constant rate.Br Med J (Clin Res Ed). 1985 Feb 2;290(6465):341-4. doi: 10.1136/bmj.290.6465.341. Br Med J (Clin Res Ed). 1985. PMID: 3917812 Free PMC article.
-
Heparin therapy.Am Fam Physician. 1974 Sep;10(3):163-8. Am Fam Physician. 1974. PMID: 4413661 No abstract available.
-
Effect of anticoagulant treatment measured by fibrinopeptide A (fpA) in patients with venous thrombo-embolism.Thromb Res. 1980 Apr 1-15;18(1-2):33-43. doi: 10.1016/0049-3848(80)90168-1. Thromb Res. 1980. PMID: 7404504 No abstract available.
-
Antithrombotic therapy in deep vein thrombosis and pulmonary embolism.Am Heart J. 1992 Apr;123(4 Pt 2):1115-22. doi: 10.1016/0002-8703(92)91070-h. Am Heart J. 1992. PMID: 1553881 Review.
Cited by
-
Low-Molecular-Weight Heparins: Reduced Size Particulate Systems for Improved Therapeutic Outcomes.Molecules. 2018 Jul 18;23(7):1757. doi: 10.3390/molecules23071757. Molecules. 2018. PMID: 30021958 Free PMC article. Review.
-
Issues Regarding the Use of Heparin Following Streptokinase Therapy.J Thromb Thrombolysis. 1995;2(1):5-10. doi: 10.1007/BF01063155. J Thromb Thrombolysis. 1995. PMID: 10639209
-
Predicting Therapeutic Response to Unfractionated Heparin Therapy: Machine Learning Approach.Interact J Med Res. 2022 Sep 19;11(2):e34533. doi: 10.2196/34533. Interact J Med Res. 2022. PMID: 35993617 Free PMC article.
-
Heparin-Mimicking Polymers: Synthesis and Biological Applications.Biomacromolecules. 2016 Nov 14;17(11):3417-3440. doi: 10.1021/acs.biomac.6b01147. Epub 2016 Oct 14. Biomacromolecules. 2016. PMID: 27739666 Free PMC article. Review.
-
[A fatality caused by heparin overdose].Z Rechtsmed. 1989;103(2):147-53. doi: 10.1007/BF01258919. Z Rechtsmed. 1989. PMID: 2609791 German.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources